1257850-86-4

Basic information

• Product Name: (R)-4-Boc-3-morpholinecarbaldehyde
• Synonyms: (R)-4-Boc-3-morpholinecarbaldehyde;(3R)-3-Formyl-4-morpholinecarboxylic acid tert-butyl ester;(R)-3-Formyl-morpholine-4-carboxylic acid tert-butyl ester;(R)-tert-Butyl 3-formylmorpholine-4-carboxylate;(3R)-4-Boc-3-formyl-morpholine
• CAS NO: 1257850-86-4
• Molecular Formula: C10H17NO4
• Molecular Weight: 215
• Mol File: 1257850-86-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 309℃
• Flash Point: 141℃
• Appearance: /
• Density: 1.180
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -3.28±0.40(Predicted)
• CAS DataBase Reference: (R)-4-Boc-3-morpholinecarbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-Boc-3-morpholinecarbaldehyde(1257850-86-4)
• EPA Substance Registry System: (R)-4-Boc-3-morpholinecarbaldehyde(1257850-86-4)

Safety Data

• Hazardous Substances Data: 1257850-86-4(Hazardous Substances Data)

Usage

General Description

"(R)-4-Boc-3-morpholinecarbaldehyde" is a chemical compound that falls under the category of specialized bioactive and fine chemical products. It is typically utilized in various forms of biochemical research and pharmaceutical development. (R)-4-Boc-3-morpholinecarbaldehyde holds significant importance due to its role in biological research as well its potential use in the synthesis of more complex chemical structures. The specificity of the "(R)-4-Boc-3-morpholinecarbaldehyde" structure and its properties allow for targeted and precise functionality in these research-study applications. It’s crucial to handle this chemical under professional supervision as its safety and health impacts are not widely studied.

Upstream product

• 215917-99-0 (R)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 
• 473923-56-7 tert-Butyl 3-(hydroxymethyl)-4-morpholinecarboxylate 
• 869681-70-9 (R)-morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 
• 714971-28-5 (S)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 
• 110167-20-9 4-benzyl-3-(hydroxymethyl)morpholine 
• 106910-83-2 (rac)-3-hydroxymethylmorpholine 
• 106910-79-6 (RS)-4-benzyl-5-oxomorpholine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 212650-43-6 4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid 
• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 

Downstream Products

• 910447-70-0 tert-butyl 3-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-1-hydroxy-3-oxopropyl)morpholine-4-carboxylate 
• 885274-05-5 3-(4-(tert-butoxycarbonyl)morpholin-3-yl)propanoic acid 
• 877078-82-5 tert-butyl 3-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-1-hydroxy-3-oxopropyl)morpholine-4-carboxylate 

Relevant articles and documents

POTENT HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amytrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.

Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold

Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB). To overcome the BBB, both passive permeability and efflux transporter liability of a compound must be addressed. Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases. Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed. In addition to determining inhibitor potency and selectivity, crystal structures of most newly designed compounds complexed to various nitric oxide synthase isoforms have been determined. We have discovered a new analogue (21), which exhibits not only excellent potency (Ki 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.

ERBB/BTK INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compou